Skip to main content

Antibe Therapeutics Inc(ATE-T)
TSX

Today's Change
Real-Time Last Update

Antibe Therapeutics: Stocks trading at Less Than Cash Value on (ATE)

The Globe and Mail - Sun Sep 11, 2022
Stocks Trading at Less than Cash Value

Antibe Therapeutics is among the group of Toronto Stock Exchange companies currently trading at less than cash value. This means companies whose current share price is less than the cash per share on their balance sheet or stocks with more cash than market cap.

This report is generated monthly. It also shows the value of cash net debt per share to show how much cash per share would be left if the debt was paid off. Stocks in this category are held primarily for speculation. Companies can have more cash per share than the actual share price for a number of reasons including that they just raised capital, are in industries that experience high burn rates and will eat through the cash quickly or there is a lot of uncertainty about the future of the company. Companies earning a positive net income will have a price-to-earnings, or P/E, ratio greater than zero and are worth exploring in more detail.

Symbol

Name

Close Price

Shares Outstanding

P/E

P/B

Cash per Share

Net Cash per Share

ATE-TAntibe Therapeutics1.1551,38001.1761.41.4
ETX-T0.085334,0941.1180.1830.39-0.1
CSM-TClearStream Energy Servs0.07109,9921.7500.37-1.41
TRZ-TTransat A.T.4.9737,7474.14742.0679.17-17.54
TS-B-TTorstar0.7481,33600.3550.850.68
MNS-T17.240023,651.7511,260.75
VLE-TValeura Energy0.4686,58500.6980.490.35
S-TSherritt International0.38397,28500.2630.4-0.71
MRV-TNuvo Pharmaceuticals1.2311,38801.1632.39-6.15
MNT-T23.0240023,651.7511,260.75
RCG-TRF Capital Gr2.22158,10811.11.3593.292.53
TEI-TToscana Energy Income0.005145,1280.0590.0650.01-0.19

More about Antibe Therapeutics

Antibe Therapeutics Inc is a healthcare company. It is engaged in the development of patents and out-licensing of improved compounds of existing drugs. The company has two primary business segments: Antibe Therapeutics and Citagenix.

Artificial intelligence at Report on Business

Report on Business scans market data using algorithms to process large quantities of information. The results are specialized reports produced through automation. Ongoing ROB project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities.